|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The observed biological difference in circulating granulocyte involvement by the JAK2 V617F clone necessitates a sensitive molecular assay for the diagnostic investigation of thrombocytosis.
|
16916724 |
2006 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
|
16990759 |
2006 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We show that transplantation of JAK2(V617F)-transduced bone marrow into BALB/c mice induces MPD reminiscent of human PV, characterized by erythrocytosis, granulocytosis, extramedullary hematopoiesis, and bone marrow fibrosis, but not thrombocytosis.
|
17145859 |
2006 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The lack of thrombocytosis suggests that additional events may be required for JAK2 V617F to cause ET, but qualitative platelet abnormalities induced by JAK2 V617F may contribute to the hemostatic complications of PV.
|
17183644 |
2006 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
|
17194663 |
2006 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Therefore, JAK2 mutation screening holds the promise of a decisive diagnostic test in PV while being complementary to histology for the diagnosis of ET and PMF; the combination of molecular testing and histologic review should also facilitate diagnosis of ET associated with borderline thrombocytosis.
|
17488875 |
2007 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis.
|
17507997 |
2007 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, JAK2 mutation screening has now become a front-line diagnostic test in the evaluation of both "erythrocytosis" and thrombocytosis and the 2001 World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis have now been revised to incorporate JAK2V617F mutation screening.
|
18032973 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 x 10(9)/l.
|
18040685 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
|
18059483 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis.
|
18160670 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
In 6/11 RARS-T patients the allelic ratio of JAK2-V617F was above 50%, indicating the presence of cells homozygous for the mutation.
|
18166783 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
His postoperative management included the examination of his peripheral blood as well as bone marrow, which confirmed that the cause of his elevated platelet count was due to JAK2 V617F mutation that is treated by hydroxyurea and aspirin after being discharged from the hospital.
|
18534315 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
JAK2 and MPL mutations in myeloproliferative neoplasms.
|
18566540 |
2008 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
JAK2 617 HP is an adequate test in differential diagnosis for both erythrocytosis and thrombocytosis.
|
18575865 |
2008 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
LHGDN |
JAK2 617 HP is an adequate test in differential diagnosis for both erythrocytosis and thrombocytosis.
|
18575865 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The two patients who developed thrombocythemia during infancy were JAK2 V617F-negative.
|
18802948 |
2008 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.
|
19287382 |
2009 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
|
19287384 |
2009 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The V617F JAK2 mutation was absent within the patients with secondary erythrocytosis or thrombocytosis.
|
19939582 |
2011 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
|
20154217 |
2010 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
|
20194893 |
2010 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A 66-year-old man who presented with progressive and marked thrombocytosis but normal hemoglobin was diagnosed to have essential thrombocythemia upon the demonstration of JAK2 V617F mutation.
|
20633767 |
2010 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data also support the hypothesis that level of JAK2(V617F) expression influences the MPN phenotype: higher levels favor erythrocytosis whereas lower levels favor thrombocytosis.
|
21242185 |
2011 |